ATE353957T1 - Verwendung von lezithin-cholesterin- azetyltransferase für die behandlung von atherosklerose - Google Patents

Verwendung von lezithin-cholesterin- azetyltransferase für die behandlung von atherosklerose

Info

Publication number
ATE353957T1
ATE353957T1 AT96940403T AT96940403T ATE353957T1 AT E353957 T1 ATE353957 T1 AT E353957T1 AT 96940403 T AT96940403 T AT 96940403T AT 96940403 T AT96940403 T AT 96940403T AT E353957 T1 ATE353957 T1 AT E353957T1
Authority
AT
Austria
Prior art keywords
atherosclerosis
treatment
acetyl transferase
lecithin cholesterol
cholesterol acetyl
Prior art date
Application number
AT96940403T
Other languages
English (en)
Inventor
Silvia Santamarina-Fojo
Jeffrey M Hoeg
H Bryan Brewer Jr
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE353957T1 publication Critical patent/ATE353957T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
AT96940403T 1995-11-09 1996-11-08 Verwendung von lezithin-cholesterin- azetyltransferase für die behandlung von atherosklerose ATE353957T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US640095P 1995-11-09 1995-11-09

Publications (1)

Publication Number Publication Date
ATE353957T1 true ATE353957T1 (de) 2007-03-15

Family

ID=21720680

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96940403T ATE353957T1 (de) 1995-11-09 1996-11-08 Verwendung von lezithin-cholesterin- azetyltransferase für die behandlung von atherosklerose

Country Status (8)

Country Link
US (1) US6635614B1 (de)
EP (1) EP0871713B1 (de)
AT (1) ATE353957T1 (de)
AU (1) AU728257B2 (de)
CA (1) CA2236982C (de)
DE (1) DE69636907T2 (de)
ES (1) ES2283007T3 (de)
WO (1) WO1997017434A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69836626T2 (de) * 1997-04-11 2007-04-05 Takeda Pharmaceutical Co. Ltd. Proteine mit lecithin-cholesterin acetyltransferase-ähnlicher aktivität, deren herstellung und verwendung
WO2001005943A2 (en) * 1999-07-14 2001-01-25 Betagene, Inc. Lcat recombinant cell line compositions and methods
WO2003040369A2 (fr) * 2001-09-17 2003-05-15 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003062416A1 (fr) * 2002-01-21 2003-07-31 Takeda Chemical Industries, Ltd. Procede de criblage d'agents preventifs et de remedes pour l'arteriosclerose
SE0201581D0 (sv) 2002-05-29 2002-05-29 Scandinavian Biotechnology Res New improved acyltransferase
WO2008002591A2 (en) 2006-06-26 2008-01-03 Amgen Inc Methods for treating atherosclerosis
EA201070187A1 (ru) 2007-07-26 2010-08-30 Эмджен Инк. Модифицированные ферменты лецитин-холестерин ацилтрансферазы
NZ595789A (en) 2009-04-29 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
JP5759988B2 (ja) * 2009-06-12 2015-08-05 アルファコア ファーマ リミテッド ライアビリティ カンパニーＡｌｐｈａｃｏｒｅ Ｐｈａｒｍａ Ｌｌｃ 貧血および赤血球機能不全を治療するためのｌｃａｔの使用
CN104220460A (zh) 2011-12-08 2014-12-17 安姆根有限公司 激动人lcat抗原结合蛋白和它们在疗法中的用途
US10495652B1 (en) * 2012-04-13 2019-12-03 Roar Holding Llc Determination of LCAT
EP3706781A4 (de) * 2017-11-07 2021-07-21 Alphacore Pharma LLC Verfahren zur behandlung und zum schutz gegen herzkrankheiten, herz-kreislauf-erkrankungen und verwandte zustände und symptome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943527A (en) * 1985-10-04 1990-07-24 California Biotechnology Inc. Mature apoai protein production under serum free culturing conditions
EP0239631A4 (de) * 1985-10-04 1989-01-12 Biotech Res Partners Ltd Rekombinante apolipoproteine und verfahren.
US5049488A (en) * 1985-11-08 1991-09-17 Genentech, Inc. Method and nucleic acid for the preparation of lecithin:cholesterol acyltransferase
DE4128288A1 (de) * 1991-08-27 1993-03-04 Boehringer Ingelheim Kg Verwendung von paf-antagonisten zur behandlung und diagnose von cholestase und anderen krankheiten, die durch einen erhoehten lipoprotein-x spiegel gekennzeichnet sind
EP0644897B1 (de) * 1992-06-12 1998-09-16 N.V. Innogenetics S.A. Peptide und Proteine, Verfahren zur Ihren Herstellung und die Verwendung als Cholesterol-Annehmer
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
FR2718329B1 (fr) * 1994-03-21 2002-09-20 Rhone Poulenc Rorer Sa Lapin transgénique sensibilisé aux dyslipoprotéinémies.
FR2731710B1 (fr) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique

Also Published As

Publication number Publication date
US6635614B1 (en) 2003-10-21
CA2236982C (en) 2010-07-27
WO1997017434A2 (en) 1997-05-15
DE69636907D1 (de) 2007-03-29
DE69636907T2 (de) 2007-11-22
AU7729396A (en) 1997-05-29
EP0871713B1 (de) 2007-02-14
EP0871713A2 (de) 1998-10-21
ES2283007T3 (es) 2007-10-16
CA2236982A1 (en) 1997-05-15
AU728257B2 (en) 2001-01-04
WO1997017434A3 (en) 1997-06-19

Similar Documents

Publication Publication Date Title
Jaffe et al. Correlation between thrombin-induced prostacyclin production and inositol trisphosphate and cytosolic free calcium levels in cultured human endothelial cells.
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE353957T1 (de) Verwendung von lezithin-cholesterin- azetyltransferase für die behandlung von atherosklerose
PT841928E (pt) Formulacao de libertacao prolongada de d-trep-metilfenidato
DE69616333T2 (de) Thip zur behandlung von schlafstörungen
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
BG103190A (en) Substituted pyrimidine derivatives and their pharmaceutical application
DE69625691T2 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
RU94031747A (ru) Соединения и способы лечения
ATE205365T1 (de) Enzymatische behandlung von kakao
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE308327T1 (de) Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE69805973T2 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69634951D1 (de) Topische verwendung von betulinsäure zur behandlung bösartiger melanome
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
ATE338563T1 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus- interferon
HUP9800731A2 (hu) Eljárás ivarsejt osztódás stimulálására
DE69433848D1 (de) Bpi-protein-produkte für definierte funktionen des reticuloendothelialen systems
NO20003224D0 (no) Forbindelser med inhiberende aktivitet for lipidmetabolisme samt fremgangsmÕte ved fremstilling derav
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
ATE213163T1 (de) Verfahren zur behandlung von motorischen defiziten
ATE202552T1 (de) Benzamide für behandlung von neurodegenerativen störungen
IE860227L (en) Monoclonal anti-alpha-amylase antibody
DE69620786T2 (de) Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties